Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
To order this detailed 500+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html
Key Inclusions
§
A detailed assessment
of the current market landscape featuring over 280 stem cell-based therapies
approved / under clinical development, including information on drug / therapy
developer(s) (such as year of establishment, company size and location of
headquarters), phase of development (marketed, phase III, phase II, phase I),
source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells
(hematopoietic, mesenchymal, progenitor and others), stem cell lineage
(amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes,
corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal
cells and others), stem cell potency
(multipotent and pluripotent), target indication(s), key therapeutic area(s),
route of administration (intravenous, intramuscular, intraarticular, intramyocardial,
intracoronary, intrathecal and others), and information on number of stem
cells, special drug / therapy designation (if any), commercial geographical
rights. In addition, information on the various technology platforms being
actively used for the development of stem cell therapies has been provided.
§
Identification of
contemporary market trends, depicted using five schematic representations,
which include [A] a tree map representation of the various industry players
involved in the development of stem cell therapies, distributed on the basis of
the target therapeutic areas of pipeline candidates and size of the companies
(small, mid-sized and large companies), [B] a schematic world map
representation, highlighting the geographical locations of various industry
players, [C] a bubble analysis comparing the leading players engaged in the
generation of stem cell therapies, on the basis of parameters such as pipeline
strength (based on the number of therapy candidates developed by a particular
company, across different phases of development), number of target indications
and the size of the developer company, [D] an insightful grid analysis,
highlighting the distribution of therapy candidates on the basis of phase of
development, source of stem cell and target therapeutic areas, and [E] an informative
heptagon representation, highlighting the distribution of marketed / clinical
stem cell therapies across popular target therapeutic areas (based on the
number of therapy candidates across each target therapeutic areas).
§
Detailed profiles of
the key industry players engaged in the development of stem cell-based
therapies, featuring a brief overview of the company (such as year of
establishment, company size, location of headquarters, key members of the
executive team and financial information (if available)), details of their
respective product portfolio and an informed future outlook.
§
An assessment of over
20 commonly targeted therapeutic indications and details of stem cell-based
therapies being developed to treat the same conditions, highlighting disease
specific epidemiological facts, contemporary methods of diagnosis, and
currently available treatment options and their side-effects.
§
A detailed
proprietary 2×2 representation that was developed to assess the current market
scenario (in terms of existing competition and growth opportunities) across
emerging and established market segments.
§
An in-depth analysis
of more than 1,500 grants that have been awarded to research institutes engaged
in stem cell therapy-related projects, in the period between 2015 and 2019
(till November), including analysis based on important parameters, such as year
of grant award, amount awarded, administration institute, funding institute
center, funding institute center, support period, spending categorization,
funding mechanism, grant type, responsible study section, focus area, prominent
program officers, and type of recipient organizations. It also features a
detailed analysis based on the types of stem cell (based on origin, source,
potency and lineage) and therapeutic areas, along with a multivariate grant
attractiveness analysis based on parameters, such as amount awarded, support
period, grant type, number of indications under investigation.
§
A detailed clinical
trial analysis on more than 540 completed, ongoing and planned studies of
various stem cell therapies, highlighting prevalent trends across various
relevant parameters, such as current trial status, trial registration year,
phase of development, study design, leading industry sponsors (in terms of
number of trials conducted), study focus, type of stem cells, target
indication(s), target therapeutic area(s), enrolled patient population and
regional distribution of trials.
§
A review of the key
aspects related to the manufacturing of stem cell therapies, including [A] a
detailed discussion on processes and protocols, highlighting the need to
outsource various aspects of stem cell therapy development and manufacturing
operations, [B] an assessment of the current market landscape of contract
manufacturers, providing information on stem cell-focused service providers
(such as year of establishment, company size, location of headquarters and
manufacturing facilities), scale of stem cell manufacturing (commercial,
clinician and preclinical), services offered in addition to manufacturing
(culture development / set up, stem cell identification / validation, stem cell
banking, regulatory consultancy, fill / finish, cryopreservation and stem cell
logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful
Harvey ball analysis to identify the key performance indicators / key
considerations that industry stakeholders are likely to take into consideration
while selecting a suitable CMO / CRO partner.
§
A detailed market gap
analysis in order to develop a realistic understanding of the demand and supply
dynamics within this field, comparing both clinical and commercial capabilities
of therapy developers and the availability and capabilities of contract
manufacturers, across different geographies.
§
An elaborate
discussion on the various strategies that can be adopted by stem cell therapy
developers across different stages of product development and commercialization
(prior to product launch, post-marketing, and near patent expiry), and the key
strategies that have been adopted by drug developers for the commercialization
of their proprietary product candidates.
§
An analysis of
contemporary trends, as observed on the Google Trends portal, for the period
2015-2019 and insights from the recent news articles related to stem cell
therapies indicating the increasing popularity of this upcoming field of
research.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Source
of stem cell
§ Allogeneic
§ Autologous
§ Origin
of stem cell
§ Adult
§ Embryonic
§
Type of stem cell
§ Hematopoietic
§ Mesenchymal
§ Progenitor
§ Others
§ Lineage
of stem cell
§ Adipose
Tissue
§ Bone
Marrow
§ Cord
Blood
§ Others
To request
for Customize Report – https://www.rootsanalysis.com/reports/296/request-customization.html
§ Route
of Administration
§ Intraarticular
§ Intracoronary
§ Intramuscular
§ Intramyocardial
§ Intrathecal
§ Intravenous
§ Surgical
Implantations
§ Others
§ Therapeutic
Area
§ Autoimmune
/ Inflammatory Disorder
§ Cardiovascular
Disorders
§ Metabolic
Disorder
§ Musculoskeletal
Disorders
§ Oncological
Disorders
§ Neurological
Disorders
§ Ophthalmic
Disorders
§ Others
§ End
Users
§ Ambulatory
Surgery Centers
§ Hospitals
§ Specialty
Clinics
§ Key
Geographies
§ North
America
§ Europe
- Asia-Pacific
and Rest of the World
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/296/request-sample.html
Key Questions Answered
§
Who are the leading developers of stem cell therapies?
§ Which
types of clinical conditions can be treated using stem cell therapies?
§ Which
cell lineages and types of stem cells are commonly used for therapy
development?
§ What
kind of key commercialization strategies are being used by stem cell therapy
developers?
§ Who
are the key contract service providers engaged in this domain?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be
interested in the following titles:
1.
Stem Cell Therapy
Contract Manufacturing Market, 2019-2030
2.
Antibody Drug
Conjugates
Market (5th Edition), 2019-2030
3.
Cell and Advanced
Therapies Supply Chain Management Market, 2019-2030: Focus on Technological
Solutions
4.
Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Comments
Post a Comment